Jemperli
Neoadjuvant Jemperli Continues to Show 100 Percent Complete Response Rate in dMMR Rectal Cancer
Premium
The immunotherapy led to durable responses, with 24 patients experiencing a complete response for at least one year.
GSK's Jemperli Plus Chemo Approved in Europe for Frontline dMMR/MSI-H Endometrial Cancer
The European Commission also converted a conditional approval of Jemperli monotherapy in second-line endometrial cancer to full approval.
CHMP Recommends GSK's Jemperli Plus Chemo as Frontline Endometrial Cancer Treatment in Europe
The committee recommended regulators approve Jemperli plus chemo for patients with dMMR or MSI-high advanced tumors based on data from the RUBY trial.